Descripción del proyecto
La función de la flora intestinal en la prevención de enfermedades cardiovasculares
Las enfermedades cardiovasculares (ECV) son una de las principales causas de mortalidad en Europa. Estudios clínicos y epidemiológicos indican que el consumo de alimentos con polifenoles protege contra las ECV. También se ha descubierto que la flora intestinal constituye un agente esencial en la regulación de la bioactividad de los polifenoles. Ensayos clínicos recientes han revelado que la composición de la flora intestinal es fundamental para la eficacia de los polifenoles. El proyecto PolyBiota, financiado con fondos europeos, proporcionará nuevos conocimientos sobre la función de la flora intestinal como un agente clave en la prevención de las ECV a través de los efectos beneficiosos de los alimentos ricos en polifenoles. La investigación se centrará en el papel de la flora intestinal como mediador de los mecanismos asociados con la prevención y la mejora del tratamiento de las ECV.
Objetivo
Cardiovascular disease (CVD) is the main cause of mortality in Europe with an annual estimated cost of €210 billion. Different European Public Health strategies have targeted diet to prevent/treat CVDs. This multidisciplinary and multi-institutional project aims to provide new insights into the role of the gut microbiota as a key player in the beneficial effects against CVDs associated with the consumption of Polyphenols (PPs)-rich foods. PolyBiota will be developed through innovative research at one of the epicenters of PPs research (CEBAS-CSIC) and secondment at FISABIO (Valencia, Spain). Epidemiological, clinical, and preclinical studies suggest that the consumption of PPs-containing food protects against CVDs (i.e modulating angiogenesis in atherosclerotic plaques) . However, these benefits are not always observed due to the high inter-individual variability. The gut microbiota has emerged as an essential player that regulates the bioactivity of PPs. Recent clinical trials indicate that the gut microbiota composition play a critical role in the activity of PPs improving CV biomarkers. These studies open a new door to investigate how the interaction PPs-gut microbiota can modulate mechanisms associated with the improvement of CVDs. PolyBiota will investigate: i) role of the gut microbiota as mediator of the effects of the consumption of Ellagitannins (ETs)-/urolithin (Uro)-A- and Isoflavones (IsoFlv)-/equol-enriched diets on angiogenesis/mechanisms related in untreated and antibiotic-treated animals, ii) the “prebiotic-like effect” of the ETs, Uro-A, IsoFlv and equol consumption on the gut microbiota population, iii) the effects of the gut microbiota-biosynthesized messenguers or the ETs- and IsoFlv-derived metabolites on in vitro tubulogenesis. PolyBiota shows an innovative approach combining cutting-edge techniques, “big data” management, endothelial cells, and in vivo animal models providing a holistic scene of the Diet-Gut Microbiota-Host interaction.
Ámbito científico
Palabras clave
Programa(s)
Régimen de financiación
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Coordinador
28006 Madrid
España